Skip to content

Age of BLood Evaluation (ABLE) trial in the resuscitation of critically ill patients

Age of BLood Evaluation (ABLE) trial in the resuscitation of critically ill patients: a multicentre randomised controlled superiority clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN44878718
Enrollment
2510
Registered
2008-08-22
Start date
2008-12-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients requiring red cell transfusions and having a probability of 28-day all-cause mortality exceeding 25% Signs and Symptoms Transfusions

Interventions

Experimental: Transfusions of red cells stored less than 8 days issued by the local blood bank. This will be applied up to discharge from the hospital or step-down unit (not more than 90 days post-ra

Sponsors

Sainte-Justine Hospital Research Centre (Centre de recherche du CHU Sainte-Justine) (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who: 1. Have had a request for a first red cell unit transfusion in the Intensive Care Unit (ICU), and 2. Have an anticipated length of invasive and/or non-invasive continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BIPAP) mechanical ventilation of at least 48 hours once enrolled, as estimated by the attending physician

Exclusion criteria

Exclusion criteria: Investigators and research assistants will exclude patients: 1. Who are less than 16 years of age 2. Who were previously enrolled in the ABLE study 3. Who have already been transfused with red cells during the current hospitalisation 4. Who have an obvious terminal illness documented in the medical record with a life expectancy of less than 3 months 5. Who have undergone routine cardiac surgical care 6. Where a decision to withdraw/withhold some critical care had been made 7. Who are obviously brain dead Investigators, research assistants and blood bank personnel will also exclude patients: 8. When there are no red cells with a storage time of 7 days or less available in the blood bank that cannot be transported from the blood supplier 9. Who require more than 1 unit of uncross-matched red cells 10. With a known objection to blood transfusions 11. With autologous blood donations 12. Who pose difficulties in securing blood products (rare blood groups), and who are difficult to match

Design outcomes

Primary

MeasureTime frame
90-day all cause mortality.

Secondary

MeasureTime frame
1. Other mortality rates and survival times as measured at ICU discharge, hospital discharge, 28 days and 6 months post-discharge 2. Number of cases of multiple organ dysfunction syndrome (MODS), highest number of organ failures per patient, MODS score and time to development of MODS as measured while in the ICU 3. Serious nosocomial infections including: 3.1. Nosocomial pneumonia 3.2. Deep tissue infections (e.g. peritonitis, mediastinitis) 3.3. Bacteraemia from organisms not considered normal skin flora and judged important enough to treat by the attending team, as measured while in the ICU 4. Adverse events and transfusion reactions as measured while in ICU 5. Length of stay (ICU and hospital) 6. Length of time requiring respiratory, haemodynamic and renal support as measured while in ICU

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 29, 2026